GGrantIndex
Sort

146,196 grants matching diabetes

Islet Dysregulation in Infants with Congenital Hyperinsulinism

$748,419
Diva Del Carmen De Leon · Children'S Hosp Of Philadelphia · R01 · FY2020 · DK

Depression & CHD: Cellular-Molecular Mechanisms

$748,390
Edward Carlos Suarez · Duke University · R01 · FY2012 · HL

Food Prescriptions to Promote Affordable Diets that Meet RDAs Among Multi-Generational Latino Households

$748,389
Deborah A Cohen · Children'S Hospital Of Los Angeles · P50 · FY2023 · MD

CV Benefits and Safety of Glucose-Lowering Therapies in Adults with Diabetes

$748,336
Patrick J O'Connor · Healthpartners Institute · R01 · FY2016 · HL

Yale Center for Metabolic Phenotyping in Live Models of Obesity and Diabetes

$748,333
Gerald I Shulman · Yale University · U2C · FY2024 · DK

The role of irregular sleep schedules as a ubiquitous marker of chronic circadian disruption in cardiometabolic disease development

$748,329
Susan S Redline · Brigham And Women'S Hospital · R01 · FY2023 · HL

KENTUCKY HEALTHY COMMUNITIES, TOBACCO CONTROL, DIABETES PREVENTION AND CONTROL

$748,295
Steve Davis · Ky St Cabinet/Health/Family Services · U58 · FY2011 · DP

Mitigating the Effects of Structural Racism on Chronic Kidney Disease Disparities among African Americans

$748,282
Kimberly Ruth Jacob Arriola · Emory University · U01 · FY2024 · DK

Community-Based Lifestyle Promotion With Latino Women

$748,256
Deborah Koniak-Griffin · University Of California Los Angeles · R01 · FY2009 · HL

Examining the physical toll of marginalizing experiences in emerging adulthood and exploring resilience possibilities

$748,239
Noelle M Hurd · University Of Virginia · R01 · FY2022 · MD

Health Disparities and CVD: Admixture Mapping in the Jackson Heart Study

$748,233
James Graham Wilson · University Of Mississippi Med Ctr · R01 · FY2006 · HL

DNA Sequencing and Digital Gene Expression Core

$748,221
Kathleen Hartman · Division Of Basic Sciences - Nci · ZIC · FY2010 · CA

REGULATION OF EXOCYTOSIS STUDIES WITH FLIPPED SNARES

$748,164
James E Rothman · Yale University · R01 · FY2009 · GM

Computer Based Screening for Diabetic Retinopathy

$748,129
Peter N Soliz · Visionquest Biomedical, Llc · R44 · FY2012 · EY

Physiological and therapeutic effects of ANGPTL3 variants in mice and humans

$748,107
Marina Cuchel · University Of Pennsylvania · R01 · FY2022 · HL

Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

$748,101
Samuel Klein · Remd Biotherapeutics, Inc. · R42 · FY2017 · DK

Harnessing Diverse BioInformatic Approaches to Repurpose Drugs for Alzheimers Disease

$748,092
Mark W Albers · Massachusetts General Hospital · R01 · FY2021 · AG

MODULAR BIO-BEHAVIORAL CLOSED-LOOP CONTROL OF TYPE 1 DIABETES

$748,089
Boris P. Kovatchev · University Of Virginia · R01 · FY2010 · DK

Secondary Stroke prevention by Uniting Community and

$748,080
Barbara G Vickrey · University Of California Los Angeles · U54 · FY2014 · NS

Multi-Center Validation and Biologic Assessment of a Novel Pre-Transplant Biomarker Panel to Predict Liver Transplant Recipient Mortality

$748,049
Keri Elizabeth Lunsford · Rutgers Biomedical And Health Sciences · R01 · FY2024 · DK

Metabolomic Quantitative Trait Locus (mQTL) Genetic Mapping in Human CVD

$748,043
Svati H. Shah · Duke University · R01 · FY2009 · HL

Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers

$748,026
Emily Nicole Corbett Manoogian · Salk Institute For Biological Studies · R01 · FY2025 · DK

Ambulatory blood pressure and falls in older treated patients with hypertension

$748,004
Kristi Reynolds · Kaiser Foundation Research Institute · R01 · FY2020 · HL

A Graphene Nanoparticle-Based X-ray Computed Tomography Contrast Agent ForSubjects At Risk for Contrast Induced Nephropathy

$748,000
Jimmy Deon Toussaint · Theragnostic Technologies, Inc. · R44 · FY2018 · DK

A Graphene Nanoparticle-Based X-ray Computed Tomography Contrast Agent ForSubjects At Risk for Contrast Induced Nephropathy

$748,000
Jimmy Deon Toussaint · Theragnostic Technologies, Inc. · R44 · FY2019 · DK